Business
PetLife Issues Special Letter to Shareholders
PetLife Issues Special Letter to Shareholders.
About this update from Petlife Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n PetLife Issues Special Letter to Shareholders\n \n \nPetLife Issues Special Letter to Shareholders\n \n BEVERLY HILLS, CA--(Marketwired - Sep 3, 2014) -  PetLife Pharmaceuticals, Inc. (PINKSHEETS: EVGI) (PINKSHEETS: EVGID), today issued the following Special Letter to Shareholders from its Founder and Chief Executive Officer, Arthur G. Mikaelian, Ph.D. \n Dear Shareholder:\n PetLife's recent transition to a publicly traded company was a major milestone for our company. I would like to welcome all of our new shareholders, and take this opportunity to discuss our position, strategy and goals for the next twelve months.\n PetLife's sister company Medolife, which I founded in 2007, has been successfully marketing its lead product Escozine to humans for cancer prevention and treatment through direct sales in 40 countries since 2007; while in the US Escozine for humans is sold as a high-potency nutraceutical. Since 2004, in conjunction with private investors over $10 million has been invested in R&D in Escozine (for humans) and substantial scientific documentation has been amassed, worldwide, of its effectiveness.\n There is a distinct similarity of the cellular biology between humans, dogs and cats. This knowledge, combined with the growing body of pre-clinical research we have gathered and established over the years including from the UCSD Moores Cancer Center (2012), continues to demonstrate the effectiveness of Escozine's ability to kill cancer cells. Recently, PetLife licensed the exclusive worldwide rights to the intellectual property behind Escozine for humans -- to formulate, package and market a new product line, \"Escozine for Pets™.\"\n PetLife has developed, and next month will launch, a new generation of high potency veterinary nutraceuticals that targets malignant cells, based on the same patented \"Escozine\" formula and production process that uses a special polarization technology to potentiate the main ingredients to substantially increase their effectiveness. \n The polarized main ingredients in our products have been demonstrated as a preventative, and a treatment, of cancer to improve quality and extend longevity of life -- as an alternative to conventional chemotherapy. It has also been shown to be effective in combination with chemotherapy in killing cancer cells. Now, cats and ...